Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Xeris Biopharma Holdings Earnings Call: Key Takeaways

Xeris Biopharma delivered a strong Q3 with 44% revenue growth, significantly raising 2030 revenue targets to over $1 billion driven by Recorlev momentum.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthRecorlev up 93% to $71.5M; Gvoke down 14% to $21.7M; Keveyis up 9%.
Mgmt ConfidenceExtremely high; described trajectory as a 'new growth curve' and 'spectacular'.
Demand VisibilityRecord referrals and new patient starts for Recorlev; Gvoke prescriptions up 20% sequentially.
Margin TrendsGross margin improved to 88% from 85% due to favorable product mix.
Op. LeverageAdjusted EBITDA grew 77% to $30.8M, outstripping 44% revenue growth.
Vol vs PriceVolume-led; Gvoke prescriptions grew 5% YoY despite revenue decline from adjustments.
Segment GrowthRecorlev is the primary driver; Keveyis delivered fourth consecutive growth quarter.
New ClientsRecord number of new referrals and new patient starts in Q3.
Capex & DebtPrioritizing commercial investment and XP-8121 pipeline over M&A for now.
RegulatoryInitiating XP-8121 Phase 3 Cornerstone study by year-end 2026.
CommentaryShifted from 'build to yield' phase following January commercial team expansion.
New LaunchesXP-8121 Phase 3 launch imminent; potential commercial launch in 2030.

Growth

Total revenue grew 44% to $107.2M; Recorlev revenue surged 93% to $71.5M.

Outlook

Raised 2030 revenue outlook to $1B+; Recorlev $1B annual target accelerated by 3-4 years.

Risks

Gvoke faced a $4M one-time Medicaid gross-to-net adjustment; Recorlev access remains restricted by prior authorizations.

Source

The company's earnings call, NASDAQ: XERS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Xeris Biopharma Holdings, Inc.: key numbers

Share price
$16.70Close, Nov 16
Market cap
$3.05B
Shares outstanding
182.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Xeris Biopharma Holdings, Inc.

All →
4:32 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock

Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).

Value
$312K
Shares
25,000
Price
$12.49
Holding change
-1.6%
Trade date
Nov 5, 2026
4:10 PM ET 10-Q
Financial Results ▶ Call

Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY

Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.

Key figure
Net income $11.3M · +1718.0% YoY
7:14 AM ET 8-K
Financial Results

Xeris Biopharma Holdings Financial Results

Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.

“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”

John Shannon, Chairman and Chief Executive Officer

“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”

John Shannon, Chairman and Chief Executive Officer
4:59 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock

Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).

Value
$51.2K
Shares
5,000
Price
$10.23
Holding change
-0.4%
Trade date
Nov 2, 2026
4:58 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock

Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).

Value
$256K
Shares
25,000
Price
$10.23
Holding change
-2.2%
Trade date
Nov 2, 2026
4:57 PM ET Form 4
Insider Selling

Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock

Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).

Value
$153K
Shares
15,000
Price
$10.23
Holding change
-0.9%
Trade date
Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.